A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1
- PMID: 1899347
A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1
Abstract
A 36-year-old patient was investigated for a lifelong history of epistaxis and delayed bleeding after minor surgeries. Deficiencies or abnormalities of the coagulation system, of platelet function, or of factor XIII and alpha-2-antiplasmin were excluded. Consistently, however, over a period of 7 years, a high basal euglobulin fibrinolytic activity was observed that was characterized by a high tissue-type plasminogen activator (t-PA) activity, normal t-PA antigen, and undetectable plasminogen activator inhibitor type-1 (PAI-1) antigen and activity. The high specific activity of t-PA (640,000 IU/mg) and the minimal amounts of t-PA/PAI-1 complexes detected by fibrin zymography suggest that in this patient all t-PA was active. This is in striking contrast to normal plasma, where the majority of t-PA is complexed to PAI-1. Thus, in this patient, a severe deficiency of PAI-1 is associated with a delayed type bleeding tendency. Our observation underscores the importance of plasma PAI-1 for the stabilization of the hemostatic plug.
Similar articles
-
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.Br J Urol. 1997 Jul;80(1):105-10. doi: 10.1046/j.1464-410x.1997.00251.x. Br J Urol. 1997. PMID: 9240188
-
Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.J Clin Invest. 1989 May;83(5):1747-52. doi: 10.1172/JCI114076. J Clin Invest. 1989. PMID: 2496147 Free PMC article.
-
Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.Blood. 1990 Feb 1;75(3):671-6. Blood. 1990. PMID: 1688722
-
Increased levels of tissue plasminogen activator with a low plasminogen activator inhibitor-1 in a patient with postoperative bleeding.Am J Hematol. 1991 Nov;38(3):226-9. doi: 10.1002/ajh.2830380314. Am J Hematol. 1991. PMID: 1951323 Review.
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
Cited by
-
Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.Curr Drug Targets. 2011 Nov;12(12):1782-9. doi: 10.2174/138945011797635803. Curr Drug Targets. 2011. PMID: 21707474 Free PMC article. Review.
-
PAI-1 in tissue fibrosis.J Cell Physiol. 2012 Feb;227(2):493-507. doi: 10.1002/jcp.22783. J Cell Physiol. 2012. PMID: 21465481 Free PMC article. Review.
-
Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty.J Orthop Surg Res. 2018 Jan 10;13(1):8. doi: 10.1186/s13018-018-0716-2. J Orthop Surg Res. 2018. PMID: 29321050 Free PMC article.
-
Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.J Thromb Thrombolysis. 2001 May;11(3):183-93. doi: 10.1023/a:1011955018052. J Thromb Thrombolysis. 2001. PMID: 11577256 Review.
-
Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.Br Heart J. 1994 Jun;71(6):504-7. doi: 10.1136/hrt.71.6.504. Br Heart J. 1994. PMID: 8043326 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
